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Abstract 
 
Aims 
β1- and β2-adrenergic receptors (β-ARs) produce different acute contractile effects on the 
heart partly because they impact on different cytosolic pools of cAMP-dependent protein 
kinase (PKA). They also exert different effects on gene expression but the underlying 
mechanisms remain unknown. The aim of this study was to understand the mechanisms by 
which β1- and β2-ARs regulate nuclear PKA activity in cardiomyocytes. 
Methods and Results 
We used cytoplasmic and nuclear targeted biosensors to examine cAMP signals and PKA 
activity in adult rat ventricular myocytes upon selective β1- or β2-ARs stimulation. Both β1- 
and β2-AR stimulation increased cAMP and activated PKA in the cytoplasm. While the two 
receptors also increased cAMP in the nucleus, only β1-ARs increased nuclear PKA activity 
and up-regulated the PKA target gene and pro-apoptotic factor, inducible cAMP element 
repressor (ICER). Inhibition of PDE4, but not Gi, PDE3, GRK2 nor caveolae disruption 
disclosed nuclear PKA activation and ICER induction by β2-ARs. Both nuclear and 
cytoplasmic PKI prevented nuclear PKA activation and ICER induction by β1-ARs, indicating 
that PKA activation outside the nucleus is required for subsequent nuclear PKA activation 
and ICER mRNA expression. However, nuclear PKI decreased ICER up-regulation by β2-AR 
stimulation (with concomitant PDE4 inhibition) by only 30%, indicating that other mechanisms 
are involved. Down-regulation of mAKAPβ partially inhibited nuclear PKA activation upon β1-
AR stimulation, and drastically decreased nuclear PKA activation upon β2-AR stimulation in 
the presence of PDE4 inhibition.  
Conclusions 
β1- and β2-ARs differentially regulate nuclear PKA activity and ICER expression in 
cardiomyocytes. PDE4 insulates a mAKAPβ-targeted PKA pool at the nuclear envelope that 
prevents nuclear PKA activation upon β2-AR stimulation.  
Key words: adrenergic receptors - cAMP-dependent protein kinase - compartmentation - 
nucleus. 
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Introduction 
Acute stimulation of β-adrenergic receptors (β-ARs) is essential for the adaptation of cardiac 
performance to physiological needs, but persistent activation exerts deleterious effects that 
ultimately result in heart failure (HF). The normal heart mainly expresses β1- and β2-AR 
subtypes, and although both couple to the Gs/cAMP/PKA cascade, their functional effects 
differ markedly. β1- but not β2-ARs elicit strong inotropic and lusitropic responses associated 
with concerted phosphorylation of excitation-contraction coupling (ECC) proteins1, induce HF 
upon moderate expression2, 3, and promote cardiomyocyte apoptosis.4 
These diverse effects are explained by a functional compartmentation model which 
integrates alternative coupling of β2-ARs to Gi,4, 5 distinct location of receptors in specialized 
microdomains of the plasma membrane,6-10 differential coupling of β1- and β2-ARs to adenylyl 
cyclases (AC) type V and VI,11 and differential regulation by cyclic-nucleotide 
phosphodiesterases (PDEs) type 3 and 4.12 Additional differences between β1- and β2-ARs 
include receptor desensitization, with β2-ARs being more rapidly internalized than β1-ARs.13 
Another critical organizer of β-AR signalling integration is constituted by A-kinase anchoring 
proteins (AKAPs). In cardiomyocytes, AKAPs target PKA to the plasma membrane, the 
sarcoplasmic reticulum and the myofilaments for local regulation of major ECC proteins.14 
AKAPs also target PKA to other intracellular organelles such as the nucleus to regulate gene 
expression.14, 15 In cardiomyocytes, the scaffold protein muscle AKAPβ (mAKAPβ) organizes 
a complete cAMP signalling module including PKA and PDE4D3 at the nuclear envelope. 
Because PDE4D3 is phosphorylated and activated by PKA16 this constitutes a negative 
feedback loop modulating local cAMP level and PKA activity.17 Several subsequent studies 
showed that mAKAPβ assemble a much larger signalosome which major function is to 
modulate pathological hypertrophy.18-20 Upon β-AR stimulation and cAMP elevation, PKA 
activation also drives CREB-dependent transcriptional activation of inducible cAMP early 
repressor (ICER), a potent pro-apoptotic factor in cardiomyocytes.21, 22 In addition, PKA 
regulates class II histone deacetylases (HDACs) 4 and 5 in the nucleus.23-25 However, thus 
far the mechanisms that control the dynamics of nuclear PKA activity in cardiomyocytes 
remain poorly understood. We and others have used genetically-encoded PKA biosensors 
targeted to the cytoplasm and the nucleus to show temporal segregation of PKA responses 
in both compartments in neonatal and adult cardiomyocytes.26, 27 Such organization provides 
a mechanism by which acute β-AR stimulation may regulate contractility independently of 
gene expression. Our previous results also identified PDE4 as an important upstream 
regulator of nuclear PKA activity upon β-AR stimulation. However, how cAMP/PKA signalling 
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generated by β1- and β2-ARs are integrated in the nucleus of cardiomyocytes and whether 
this participates in functional differences observed upon stimulation of these receptors 
remains elusive. Here, we reveal that β1- and β2-ARs differentially regulate nuclear PKA 
activity and ICER expression in adult cardiomyocytes. We provide evidence that PDE4 
prevents activation by β2-ARs of a mAKAPβ-targeted PKA pool at the nuclear envelope 
which is required for PKA activation inside the nucleus and contributes to ICER induction.  
 
 
Methods 
An expanded methods section is provided in the online Data Supplement. 
Experimental Animals 
All procedures were performed in accordance with the European Community guiding 
principles in the Care and Use of Animals (2010/63/UE), the local Ethics Committee (CREEA 
Ile-de-France Sud) guidelines and the French decree n° 2013-118 on the protection of 
animals used for scientific purposes. Male Wistar rats were anesthetized by intraperitoneal 
injection of pentobarbital (0.1 mg/g). 
 
FRET-Based cAMP and PKA Measurements in adult rat ventricular myocytes 
After transduction of freshly isolated adult rat ventricular myocytes (ARVMs) with the 
appropriate adenoviruses, cells were subjected to FRET measurements as described.26 
 
 
Results 
 
β1- and β2-ARs differentially regulate nuclear PKA activity in adult cardiomyocytes 
To analyse the dynamics of PKA activity in the bulk cytoplasm and in the nucleus, we used 
genetically encoded A-kinase activity reporters (AKAR3) targeted to these compartments by 
the addition of a nuclear export sequence (NES), and a nuclear localizing sequence (NLS), 
respectively.28 As shown previously26 and in the pseudocolour images of Fig. 1, adenoviral 
transfer allowed robust and compartment-specific expression of these biosensors after 24h in 
adult rat ventricular myocytes (ARVMs). 
To determine how β1- and β2-ARs regulate cytoplasmic and nuclear PKA activities in ARVMs, 
we selectively stimulated these two receptors using a combination of isoprenaline (Iso) and 
either the β2-AR antagonist ICI 118,551 (ICI, 10 nM) or the β1-AR antagonist CGP 20712A 
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(CGP, 100 nM), respectively. Stimulation of cytoplasmic PKA activity by β1- and β2-ARs were 
completely abolished by 100 nM CGP and 10 nM ICI, respectively, indicating that the chosen 
concentrations of ICI and CGP in combination with Iso were appropriate for selective 
stimulation of β-AR subtypes (Supplementary Fig. 1). β1-AR stimulation led to a fast increase 
in cytoplasmic PKA activity and a robust, but slower increase in nuclear PKA activity (Fig. 1A 
and B). In contrast, β2-AR stimulation increased cytoplasmic PKA activity but had negligible 
effects on nuclear PKA activity (Fig. 1C and D). As shown in Fig. 1E, β1-AR stimulation 
increased PKA activity in a concentration-dependent manner in both compartments, whereas 
this occurred only in the cytoplasm with β2-AR stimulation (Fig. 1F). In Fig. 1G, nuclear PKA 
activation was plotted as a function of cytoplasmic PKA activation for the two receptors. The 
steeper slope of the linear regression further illustrates that β1-ARs are more efficient than 
β2-ARs to increase nuclear PKA activity, even when cytoplasmic PKA is activated at the 
same level. 
 
β1- and β2-ARs elevate cAMP in the nucleus 
Because cAMP generated by β2-ARs was reported to be locally confined29, we hypothesized 
that cAMP may not reach the nucleus upon β2-AR stimulation, hence explaining the lack of 
PKA activation in this compartment. To test this hypothesis, we generated a nuclear-targeted 
version of the cytoplasmic cAMP sensor Epac-SH187 by addition of 3 NLS at the C-terminus 
(Epac-SH187-3NLS).30 Adenoviral vectors allowed robust and compartment-specific 
expression of Epac-SH187 and Epac-SH187-3NLS in ARVMs at 24h (Supplementary Fig. 2A). 
As shown by the individual traces in Fig. 2A-D and summarized in Fig. 2E and 2F, 
stimulation of both β1- and β2-ARs increased cAMP in a concentration-dependent manner in 
the two compartments. Regardless of the receptor type or the Iso concentration employed, 
the FRET responses recorded in the nucleus were systematically higher than in the 
cytoplasm. This difference apparently reflected a greater sensitivity of the 3NLS version of 
the sensor to cAMP and not higher cAMP levels in the nucleus. When the changes in FRET 
induced by Iso in the cytoplasm were determined for both sensors following expression for 
48h, a condition for which the Epac-SH187-3NLS sensor became expressed not only in the 
nucleus, but also in the cytoplasm (Supplementary Fig. 2B), the cytoplasmic response of the 
mislocalized Epac-SH187-3NLS sensor to Iso was higher than that measured with Epac-SH187 
(Supplementary Fig. 2C). Regardless of the difference in sensitivity of the Epac-SH187 and 
Epac-SH187-3NLS sensors, the relative response in the cytoplasmic and nuclear 
compartments did not differ between β1- and β2-ARs (Fig. 2G), in contrast to what was 
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observed with the PKA sensors (Fig. 1G). Thus the lack of nuclear PKA activation cannot be 
attributed to the absence of a global nuclear cAMP elevation upon β2-AR stimulation. 
 
 
Mechanisms that prevent nuclear PKA activation by β2-ARs 
Multiple mechanisms have been proposed to compartmentalize β2-AR activation of PKA, by 
acting not only on cAMP generation and propagation but also downstream. In particular, 
receptor coupling to Gi may not only temper cAMP synthesis, but also activate alternative 
signalling pathways through βγ to circumvent the concurrent PKA activation.31, 32 To test this 
hypothesis, we inhibited Gi with pertussis toxin (PTX, 1.5 µg/mL, 2h). As a control, we 
verified that PTX effectively blocked the anti-adrenergic effect of acetylcholine on the β1-AR-
induced cytoplasmic PKA activation (Supplementary Fig. 3A and 3B). Under β2-AR 
stimulation, PTX-treated cells exhibited higher cytoplasmic PKA activity but no difference in 
nuclear PKA activation (Fig. 3A, 3B). Similarly, co-expression of AKAR3-NES or AKAR3-NLS 
with a C-terminal fragment of GRK2 (βARK-ct, supplementary Fig. 3C), that scavenges βγ 
subunits of heterotrimeric G proteins and prevents GRK2 phosphorylation and 
desensitisation of the receptor, led to a potentiation of cytoplasmic PKA activity, but was 
without effect on nuclear PKA activity (Fig. 3C, 3D). 
Another related mechanism for β2-AR compartmentalization is receptor localization to 
caveolae.6, 8, 10 To address this possibility, caveolae were disrupted by treating the cells with 
methyl-β-cyclodextrin (MβCD, 2 mM, 1h) to deplete cholesterol, or by co-expressing a 
dominant negative caveolin-3 mutant (Cav3DN) together with AKAR3-NES or AKAR3-NLS.10 
The efficiency of MβCD to deplete cholesterol was verified by filipin staining, whereas 
expression of Cav3DN was demonstrated by immunocytochemistry and western blot 
(Supplementary Fig. 4A-C). In both cases, caveolae-disrupted cells showed potentiation of 
cytoplasmic but not nuclear PKA activity upon β2-AR stimulation (Fig. 3E-H). Conversely, 
overexpression of wild type Cav3 induced a small decrease in β2-AR-stimulated cytoplasmic 
PKA activity, consistent with its previously reported effect on β2-AR-generated cytoplasmic 
cAMP (Supplementary Fig. 4D).10 
Thus, inhibition of Gi, of GRK2, and caveolae disruption potentiated β2-AR stimulation of PKA 
activity in the cell cytoplasm as expected, but did not confer PKA activation in the nucleus. 
Because recent studies emphasised the role of PDE3 and PDE4 in controlling the activation 
of discrete PKA pools by β1- and β2-ARs in cardiomyocytes33, we investigated the 
contribution of these enzymes to the regulation of cytoplasmic and nuclear PKA. We have 
shown previously26 that neither the PDE3 inhibitor cilostamide (Cil, 1 µM) alone nor the PDE4 
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inhibitor Ro-201724 (Ro, 10 µM) alone has an effect on basal PKA activity. Under β1-AR 
stimulation, PDE4 inhibition potentiated both cytoplasmic and nuclear PKA activities whereas 
PDE3 inhibition had no significant effect (Fig. 4A and 4B). In comparison, under β2-AR 
stimulation PDE3 inhibition led to a large potentiation of cytoplasmic PKA activity but was 
without effect on nuclear PKA activity (Fig. 4C and 4D). Interestingly, PDE4 inhibition had a 
similar potentiating effect on cytoplasmic PKA activity under β2-AR stimulation but in this 
case it generated a strong nuclear PKA activation (Fig. 4C and 4D). These results unveiled a 
critical role of PDE4 in controlling nuclear PKA activation. 
 
β1- and β2-ARs differentially regulate the PKA target gene and pro-apoptotic factor, 
ICER 
To assess the functional consequences of nuclear PKA activation by β1- and β2-ARs on gene 
expression, the expression of inducible cAMP early repressor (ICER), a member of the 
CREB family of transcription factors known as a critical pro-apoptotic factor in 
cardiomyocytes,21, 22, 34 was studied. β1-AR stimulation of isolated ARVMs led to a strong 
induction of ICER mRNA (Fig. 4E). This effect was potentiated by concomitant PDE4 
inhibition, but not by PDE3 inhibition (Fig. 4E). In comparison, β2-AR stimulation alone had 
no significant effect on ICER expression, but concomitant PDE4 inhibition resulted in ICER 
induction (Fig. 4F). In the absence of β-AR stimulation, neither PDE3 nor PDE4 inhibition had 
effect on ICER mRNA expression (Supplementary Fig. 5A). β1-AR stimulation of ICER mRNA 
expression was not observed in cells transduced with an adenovirus encoding the selective 
PKA inhibitor peptide (PKI) (Supplementary Fig. 5B). To examine the specific contribution of 
nuclear PKA in ICER regulation, we fused the first 25 amino acids of PKI with the red 
fluorescent protein mCherry and appended 3 NLS at the C-terminus for nuclear targeting 
(Supplementary Fig. 6A). As shown in supplementary Fig. 6B, in cardiomyocytes co-
expressing nuclear PKI with AKAR3-NLS, nuclear PKA activation by β1-ARs was abolished 
as expected. The augmentation of ICER mRNA by β1-AR stimulation alone or in combination 
with PDE4 inhibition was also suppressed by nuclear PKI expression (Supplementary Fig. 
6C and 6D). Similarly, nuclear PKI completely blocked nuclear PKA activation by β2-ARs with 
concomitant PDE4 inhibition (Supplementary Fig. 7A). However, ICER mRNA induction by 
β2-ARs with concomitant PDE4 inhibition was only partially blocked by nuclear PKI, 
suggesting that alternative mechanisms contribute to this effect (Supplementary Fig. 7B).35, 36 
Because Epac1 was localized in the perinuclear region in cardiomyocytes18, 37, similar 
experiments were conducted in cells pre-incubated with 10 µM of the Epac1 inhibitor, 
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CE3F4.38 However, as shown in supplementary Fig. 7C, Epac1 inhibition did not modify the 
stimulatory effect of β2-ARs + Ro on ICER mRNA expression. 
 
β1-AR stimulation of nuclear PKA requires an extranuclear PKA pool 
In HEK293 cells, Sample et al. showed that PDE4 controls a nuclear pool of PKA.15 In order 
to determine whether the PKA pool involved in the β1-AR-induced nuclear PKA activation is 
localized outside or inside the nucleus in cardiomyocytes, we fused the first 25 amino acids 
of PKI with the red fluorescent protein mCherry and appended a NES to the C-terminus for 
cytoplasmic targeting. As shown in the images and intensity profiles of Fig. 5A, the resulting 
constructs localized specifically in the compartment of interest in ARVMs. To verify the 
efficiency of PKA inhibition by cytoplasmic PKI, β-AR stimulation of Ca2+ transients was 
compared in Fura2-loaded and electrically paced ARVMs expressing cytoplasmic PKI, 
nuclear PKI or β-Gal. As shown in Supplementary Fig. 8, β-AR stimulation with 10 nM Iso 
increased Ca2+ transient amplitude to a similar extent in ARVMs expressing β-Gal or PKI-
3NLS, whereas these effects were absent in ARVMs expressing PKI-NES. Importantly, PKI-
NES completely blocked nuclear PKA activation in response to β1-ARs stimulation (Fig. 5B). 
Cytoplasmic PKI also blocked ICER mRNA induction by β1-ARs (Fig. 5C). These results 
show that upon β1-AR stimulation, PKA activation outside the nucleus is a prerequisite to 
enhanced nuclear PKA activity and ICER induction. 
 
Role of mAKAP in the activation of nuclear PKA by β1- and β2-ARs  
In cardiomyocytes, muscle A-kinase anchoring protein (mAKAPβ) has been shown to 
organize a cAMP-responsive network containing PKA and PDE4 at the perinuclear 
membrane.17 To study the contribution of mAKAPβ in shaping nuclear PKA responses under 
β1- or β2-AR stimulation, we used adenoviruses expressing a short hairpin RNA (shRNA) to 
reduce its expression.39 As shown in Fig. 6A and 6B, this led to ~50% decrease in mAKAPβ 
perinuclear staining 72h post-transduction. Downregulation of mAKAPβ had no effect on the 
bulk cytoplasmic PKA activity under either β1- or β2-AR stimulation in the presence of Ro 
(Supplementary Fig. 9). However, mAKAPβ silencing induced a small decrease in β1-ARs 
stimulation of nuclear PKA activity (Fig. 6C) which was not observed when PDE4 was 
inhibited (Fig. 6D). Decreasing mAKAPβ failed to unmask a nuclear PKA response to β2-AR 
stimulation (Fig. 6E) but induced a ~60% reduction of β2-AR+Ro stimulation (Fig. 6F). These 
results indicate that when PDE4 is inhibited, stimulation of β2-ARs activates a specific pool of 
PKA maintained by mAKAPβ at the nuclear envelope to increase PKA activity inside the 
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nucleus. This specific mAKAPβ-dependent PKA pool may also be mobilized upon β1-AR 
stimulation, albeit contributing to total nuclear PKA activity to a much lesser extent. 
 
 
Discussion 
 
Numerous studies have emphasized the importance of spatiotemporal control of cAMP/PKA 
pools in specific subcellular compartments for physiological regulation of cardiomyocyte 
contractile function. By comparison, the mechanisms that control nuclear PKA activity are 
less well understood, despite their critical importance for modulation of gene expression and 
long term modification of cell growth and apoptosis by β-ARs. Here, we provide the first 
evidence that β1- and β2-ARs differentially activate nuclear PKA and gene expression in adult 
cardiomyocytes. As illustrated in Fig. 7, our results support a model in which PDE4 insulates 
a mAKAPβ-targeted PKA pool at the nuclear envelope that prevents nuclear PKA activation 
and ICER induction upon β2-AR stimulation, whereas the broader β1-AR stimulation engages 
additional PKA pools to enhance nuclear PKA activity and ICER expression. 
 
In this study we found that under selective β1-AR stimulation, PKA was activated in both the 
cytoplasmic and nuclear compartments, whereas β2-AR stimulation was less efficient to 
activate cytoplasmic PKA and failed to activate nuclear PKA. The slower kinetics of nuclear 
versus cytoplasmic PKA activation observed upon β1-AR stimulation are consistent with 
previous observations using isoprenaline in cardiomyocytes26, 27 and suggest that the PKA 
holoenzyme is first activated outside the nucleus and then the catalytic subunits translocate 
inside the nucleus by diffusion, which is a slow process.40 The fact that cytoplasmic PKI 
abolished PKA phosphorylation of the nuclear-targeted PKA biosensor and induction of ICER 
upon β1-AR stimulation strongly supports this model and argues against the contribution of a 
nuclear resident pool of PKA as demonstrated in HEK293 cells.15 These results also offer a 
complementary view to the local-activation/local-action of PKA signalling which prevails in 
other subcellular compartments of cardiomyocytes.  
 
The robust increase in cytoplasmic PKA activity observed here for β1-ARs compared to the 
smaller β2-AR effect is consistent with previous real-time monitoring of PKA activity in mouse 
ventricular myocytes.41 However, this difference is not sufficient to explain the lack of nuclear 
PKA activation by β2-ARs since for a similar increase in cytoplasmic PKA activity, β1- but not 
β2-ARs activate nuclear PKA (Fig. 1G). Thus, compartmentalization rather than intensity of 
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β2-AR signals must explain their inability to induce nuclear PKA activation. However, our 
cAMP measurements with a fourth-generation cAMP FRET sensor harboring a superior 
dynamic range30 clearly showed that β2-AR stimulation elevated cAMP in the nucleus. This 
result was not expected given a previous report that β2-AR stimulation generates locally 
confined cAMP signals.29 However, a recent study using the same biosensor suggests that 
cAMP diffusivity is equivalent upon non-selective β-AR or selective β2-AR stimulation.42 Thus, 
one possibility is that the cAMP generated by β2-AR stimulation is able to diffuse to the 
nucleus even if the receptor and organelle are located at some distance from each other. But 
alternatively, β2-ARs could be localized in close proximity to the nucleus in ARVMs. Indeed, 
β2-ARs were shown to be located in T-tubules9, and T-tubules are known to extend from the 
cell surface to the nuclear envelope, where they establish close contacts with the nucleus.43, 
44 
Previous studies have proposed that alternative coupling of β2-ARs to Gi and their 
localization to caveolae circumvent β2-AR signalling by acting not only at the level of cAMP, 
but also downstream, by activating phosphatases.8, 31, 32 Accordingly, inhibition of Gi or 
disruption of caveolae potentiated β2-AR responses in the cytoplasm. However, these 
manoeuvres failed to unmask an effect of β2-AR stimulation on nuclear PKA activity, making 
it unlikely that phosphatase activation would explain the lack of β2-AR response in this 
compartment. Similarly, we show that βARK-ct overexpression potentiates β2-AR-induced 
cytoplasmic but not nuclear PKA activity. The former is consistent with inhibition of β2-AR 
desensitization, and consequent increased Gs signalling, but could also be explained by a 
decrease in Gi signalling, since it has been shown that GRK2-mediated phosphorylation of 
β2-ARs is important for β2-AR coupling to Gi45, 46 In addition, βARK-ct should also prevent the 
recruitment of PDE4D5 to β2-ARs47 as recently demonstrated.48 Based on our results, failure 
of β2-ARs to increase nuclear PKA activity was not due to coupling of β2-ARs to PDE4D5. 
Altogether, these data demonstrate that nuclear PKA activity can be dissociated from the 
bulk cytoplasmic PKA activity upon β2-AR stimulation, and that none of the above 
mechanisms is sufficient to explain the lack of nuclear PKA activation upon β2-AR 
stimulation. 
 
It is undisputed that higher rates of local cAMP degradation by PDEs participate in curtailing 
cAMP signal.49 For this reason, we investigated the role of PDE3 and PDE4, the two major 
cAMP-hydrolyzing PDEs expressed in rat cardiomyocytes,12 in tuning cytoplasmic and 
nuclear PKA responses to β-AR stimulation. Our findings show that PDE3 plays a minor role 
in regulating β1-AR stimulation, but controls cytoplasmic PKA activity in response to β2-AR 
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stimulation, whereas PDE4 acts as the main modulator of PKA activity under both β1- and β2-
AR stimulation. These data are consistent with earlier work showing that PDE4 regulates 
cAMP levels under both β1- and β2-AR stimulation, whereas PDE3 preferentially regulates 
cAMP generated under β2-AR stimulation.29 Strikingly, PDE4 inhibition unmasked nuclear 
PKA activation under β2-AR stimulation. Although several PDE4 isoforms were shown to be 
associated with β2-ARs47, 50, our cAMP measurements are not compatible with PDE4 
preventing cAMP generated by β2-AR stimulation to access the nucleus. Hence, we 
reasoned that PDE4 may act as a sink, isolating a discrete PKA pool from cAMP influx 
generated upon β2-AR stimulation.51 In cardiomyocytes, a perinuclear pool of PKA is 
maintained together with PDE4D3 by the scaffolding protein mAKAPβ, localized at the 
external membrane of the nuclear envelope17, a strategic position for nuclear regulation. Our 
results show that disrupting this PKA pool by mAKAPβ knockdown drastically reduced 
nuclear PKA activation by β2-ARs with concomitant PDE4 inhibition. This identifies mAKAPβ-
associated PKA as the main route for β2-AR control of nuclear PKA. The co-localization of 
PDE4D3 and PKA within the mAKAP complex allows efficient activation of PDE4D3 by PKA, 
rapid degradation of cAMP and restoration of basal PKA activity.17 In line with recent studies 
suggesting that PKA activation within an AKAP complex does not involve dissociation of the 
catalytic subunits52, 53, PDE4D3 within the mAKAP complex may prevent catalytic subunit 
dissociation and their translocation inside the nucleus, hence explaining the lack of nuclear 
PKA activation by β2-ARs. Upon PDE4 inhibition, abnormally elevated cAMP levels are 
reached in the complex, allowing PKA catalytic subunit dissociation and transfer to the 
nucleus. We have previously demonstrated that mAKAPβ selectively binds type 5 AC (AC5) 
in cardiomyocytes54 and others have shown that this AC5 is localized in T-tubules and is 
critical for β2-AR enhancement of ICa,L which is revealed by application of PDE3 and PDE4 
inhibitors.11 This parallel with our results further supports the existence of a pool of β2-ARs 
localized at the interface between the T-tubular membrane and the nuclear envelope (Fig. 7). 
The small impact of mAKAPβ silencing on β1-AR stimulation of nuclear PKA activity suggests 
that other PKA pools are involved, which may be controlled by distinct AKAPs. One possible 
candidate is AKAP-Lbc, which is localized in a relatively broad perinuclear region in neonatal 
myocytes.55 Indeed, AKAP-Lbc was recently shown to bind a PDE4 long isoform, the 
activation of which led to reduced forskolin-induced nuclear PKA activation and attenuated 
hypertrophic response to β-AR stimulation.56 
Recent studies have emphasized the critical role of PKA in the pro-apoptotic effects of β-
ARs.57 We have shown that nuclear PKA activation by β1-ARs is concentration-dependent 
(Fig. 1), requires sustained receptor stimulation26, and induces ICER expression (Fig. 4E and 
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Supplementary Fig. 6A), which is a strong mediator of apoptosis by decreasing Bcl-2 in 
cardiomyocytes.21 In contrast, β2-ARs do not increase nuclear PKA activity (Fig. 1) and fail to 
increase ICER expression (Fig. 4F). These results are consistent with a previous study 
showing that cardiomyocyte fate is switched from survival to death depending on the strength 
of β-AR stimulation and the balance between a β2-AR/Gi-mediated ERK1/2 pathway leading 
to Bcl-2 induction at a low concentration range of Iso, and a β1-AR-mediated 
PKA/CREB/ICER pathway leading to Bcl-2 repression at higher concentrations of Iso.34 
Thus, segregated PKA activation between the cytoplasm and the nucleus, together with 
activation of surviving signaling such as ERK1/2 is likely to contribute to the differential 
effects of low versus high levels of β-AR stimulation as well as subtype-specific effects. 
However, we further show that β2-ARs can increase ICER expression when PDE4 is 
inhibited. At variance with β1-ARs, this effect was only partially inhibited by nuclear PKI and 
not modified by the Epac1 inhibitor CE3F4 (Supplemental Fig. 7), indicating that other 
mechanisms contribute to β2-ARs regulation of ICER when PDE4 is inhibited.  
In a previous study, it was shown that in neonatal cardiomyocytes, PDE3 but not PDE4 
inhibition increased CREB phosphorylation and ICER expression and thus induced Bcl-2 
downregulation.22 These results contrast with the lack of effect of the PDE3 inhibitor 
cilostamide on basal ICER expression observed here (Supplementary Fig. 5A). This might be 
explained by differences in experimental conditions or the cell type used (adult versus 
neonatal myocytes). 
 
In conclusion, our study unveils the molecular mechanisms by which β1- and β2-ARs 
differentially regulate nuclear PKA activity and ICER expression in terminally differentiated 
adult cardiomyocytes, and identify mAKAPβ and PDE4 as critical organizers of β2-AR 
nuclear signalling. Many questions remain, however, that will need to be addressed in future 
studies. The extent to which the findings obtained here for ICER can be generalized to the β-
AR transcriptome, and the place of PKA in the control of gene expression by β-ARs versus 
other cAMP effectors will deserve further investigations. The contribution of intracellular β-
ARs located at the nuclear envelope58, 59, in endosomes60 and at the Golgi60, 61 should be 
evaluated in intact adult cardiac myocytes. In a translational perspective, it will also be 
important to determine whether the signalling routes linking β-ARs to nuclear PKA activation 
identified here in rat are conserved in larger mammals and humans. Finally, in hypertrophy 
and heart failure, there is a profound remodelling of the β-AR/cAMP/PKA pathway. 
Interestingly, while the expression of β1-ARs is reduced,62 β2-ARs and PDEs are 
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redistributed, leading to enhanced β2-ARs signalling and loss of compartmentation.9, 33, 63 
Future studies should aim to elucidate how nuclear PKA activity is controlled by β-ARs in 
diseased cardiomyocytes, which may be important for identification of new therapeutic 
targets in HF. 
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Figure legends 
 
Figure 1: Stimulation of β1- and β2-ARs induce differential activation of cytoplasmic 
and nuclear PKA activity in ARVMs. 
(A-D) Representative time course of cytoplasmic and nuclear PKA activities reported by the 
normalized Yellow Fluorescent Protein (YFP) / Cyan Fluorescent Protein (CFP) ratio in 
ARVMs transduced with Ad.AKAR3-NES (A, C) or Ad.AKAR3-NLS (B, D) for 24h at a 
multiplicity of infection (MOI) of 1000 active viral particles/cell. β1-AR stimulation was 
achieved using a combination of 10 nM isoprenaline (Iso) and 10 nM ICI 118,551 (ICI) (A, B); 
β2-AR stimulation using 100 nM Iso in combination with 100 nM CGP 20712A (CGP) (C, D). 
Pseudo-colour images of the YFP/CFP ratio were recorded at the times indicated by the 
letters on the graphs. Scale bars represent 20 µm. (E, F) Mean variation (±SEM) of the 
YFP/CFP ratio in ARVMs expressing either AKAR3-NES or AKAR3-NLS upon β1-AR 
stimulation using 1, 3 and 10 nM Iso in combination with 10 nM ICI (E) or β2-AR stimulation 
using 10, 30 and 100 nM Iso in combination with 100 nM CGP (F). Number of cells/animals 
are indicated in brackets. Statistical significance is indicated as *** p<0.001 versus ICI+Iso 1 
nM or CGP+Iso 10 nM in the cytoplasm, $$ p<0.01 versus ICI+Iso 1 nM in the nucleus, ### 
p<0.001 by nested ANOVA with Tukey’s post-hoc test. (G) Nuclear PKA activation (% 
increase in YFP/CFP ratio in ARVMs expressing AKAR3-NLS) is plotted as a function of 
cytoplasmic PKA activation (% increase in YFP/CFP ratio in ARVMs expressing AKAR3-
NES) for β1- and β2-AR stimulations. Values (±SEM) of E and F were used for this graph. 
 
Figure 2: Both β1- and β2-AR increase cytoplasmic and nuclear cAMP levels in ARVMs. 
(A-D) Representative time course of the normalized CFP/YFP ratio upon selective β1-AR 
stimulation with Iso (1, 3 and 10 nM) in combination with 10 nM ICI (A, B) or β2-AR 
stimulation with Iso (10, 30 and 100 nM) in combination with 100 nM CGP (C, D) in ARVMs 
transduced with Ad.Epac-SH187(A, C) or Ad.Epac-SH187-3NLS (B, D) for 24h at a MOI of 1000 
active viral particles/cell. Pseudo-color images of the CFP/YFP ratio were recorded at the 
times indicated by the letters on the graphs. Scale bars represent 20 µm. (E, F) Mean 
variation (±SEM) of the CFP/YFP ratio in ARVMs expressing either Epac-SH187 or Epac-SH187-
3NLS upon β1-AR stimulation (E) or β2-AR stimulation (F). Number of cells/animals are 
indicated in brackets. Statistical significance is indicated as * p<0.05; ** p<0.01; *** p<0.001 
versus ICI+Iso 1 nM or CGP+Iso 10 nM in the cytoplasm, $$ p<0.01, $$$ p<0.001 versus 
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ICI+Iso 1 nM or CGP+Iso 10 nM in the nucleus, # p<0.05, ### p<0.001, £££ p<0.001 by nested 
ANOVA with Tukey’s post-hoc test. (G) Nuclear cAMP elevation (% increase in CFP/YFP 
ratio in ARVMs expressing Epac-SH187-3NLS) is plotted as a function of cytoplasmic cAMP 
elevation (% increase in CFP/YFP ratio in ARVMs expressing Epac-SH187) in response to 
either β1- or β2-AR stimulation. Values (±SEM) of E and F were used for this graph. 
 
Figure 3: Gi proteins, caveolae and GRK2 regulate cytoplasmic but not nuclear PKA 
activation in response to β2-ARs stimulation. 
Average time course of the YFP/CFP ratio upon β2-AR stimulation in ARVMs expressing 
AKAR3-NES (A, C, E, G) or AKAR3-NLS (B, D, F, H). (A, B) ARVMs treated or not with 
pertussis toxin (PTX, 1.5 µg/mL, 2h) were exposed to 10 nM Iso plus 100 nM CGP to 
stimulate β2-ARs. In all other protocols, β2-ARs were stimulated with 30 nM Iso plus 100 nM 
CGP. (C, D) ARVMs were treated or not with 2 mM methyl-β-cyclodextrin (MβCD) for 1h. (E) 
ARVMs were co-transduced with Ad.AKAR3-NES (MOI 200) and Ad.β-Galactosidase (β-Gal, 
MOI 2000) or Ad.AKAR3-NES and an adenovirus encoding a dominant-negative Cav3 
mutant (Ad. Cav3DN, MOI 2000) for 48h. (F) ARVMs were co-transduced with Ad.AKAR3-
NLS and Ad. β-Gal or Ad.AKAR3-NLS and Ad.Cav3DN for 48h. (G) ARVMs were co-
transduced with Ad.AKAR3-NES (MOI 200) and Ad.β-Gal (MOI 1000) or Ad.AKAR3-NES 
(MOI 200) and Ad.βARK-ct (MOI 1000) for 48h. (H) ARVMs were co-transduced with 
Ad.AKAR3-NLS (MOI 200) and Ad.β-Gal (MOI 1000) or Ad.AKAR3-NLS (MOI 200) and 
Ad.βARK-ct (MOI 1000) for 48h. In each panel, the number of cells/animals are indicated in 
brackets for the different experimental conditions. Statistical significance is indicated as * 
p<0.05; ** p<0.01; *** p<0.001 by nested ANOVA with Tukey’s post-hoc test. 
 
Figure 4: PDE4 is predominant for regulation of β1- and β2-AR induced cytoplasmic 
and nuclear PKA activation. 
(A, B) Average variation of the YFP/CFP ratio upon β1-AR stimulation using 1 nM Iso plus 10 
nM ICI alone or in the presence of 1 µM cilostamide (Cil), a PDE3 inhibitor, or 10 µM Ro-
201724 (Ro) a PDE4 inhibitor in ARVMs transduced with Ad.AKAR3-NES (A) or Ad.AKAR3-
NLS (B) at MOI 1000 for 24h. (C, D) Average variation of the YFP/CFP ratio upon β2-AR 
stimulation using 30 nM Iso plus 100 nM CGP alone or in the presence of 1 µM Cil or 10 µM 
Ro in ARVMs transduced with Ad.AKAR3-NES (C) or Ad.AKAR3-NLS (D) at MOI 1000 for 
24h. Number of cells/animals are indicated in brackets. Statistical significance is indicated as 
* p<0.05; ** p<0.01; *** p<0,001; $$ p<0.01 versus β1- or β2-AR by nested ANOVA with 
Tukey’s post-hoc test. (E, F) ICER mRNA expression in ARVMs in primary culture for 24h 
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and stimulated or not by β1-ARs (100 nM Iso plus 10 nM ICI during 2h) or β2-ARs (100 nM 
Iso plus 100 nM CGP during 2h) alone or in combination with 10 µM Ro or 1 µM Cil. Number 
of animals is indicated in brackets. Statistical significance is indicated as *** p<0.001 versus 
control; $$ p<0.01, $$$ p<0.001 by Kruskal-Wallis test with Dunn’s post-hoc test (E) or one-
way ANOVA with Tukey’s post-hoc test (F).  
 
Figure 5: Cytoplasmic PKI identifies the subcellular pool of PKA involved in regulation 
of nuclear PKA activity and ICER expression by β1-ARs in cardiomyocytes. 
(A) Top, domain scheme of cytoplasmic targeted PKA inhibitor, PKI-NES. Middle, confocal 
image of an ARVM transduced with Ad.PKI–NES (MOI 250, 24h). Scale bars represent 20 
µm. Bottom, fluorescence intensity profile along the yellow line as indicated on the above 
image in arbitrary units (AU). aa, amino acids. (B) Top, confocal images of ARVMs co-
transduced with Ad.PKI-NES (MOI 250) and Ad.AKAR3-NLS (MOI 1000) for 24 h. Scale bars 
represent 20 µm. Bottom, Average time courses of the YFP/CFP ratio upon β1-AR 
stimulation using 10 nM Iso plus 10 nM ICI in ARVMs co-transduced with Ad.PKI-NES and. 
Ad.AKAR3-NLS. ARVMs co-transduced with Ad.β-Gal (MOI 250) and Ad.AKAR3-NLS (MOI 
1000) were used as control. (C) ICER mRNA expression in ARVMs transduced during 24h 
with Ad.β-Gal (MOI 250) alone, Ad.β-Gal with β1-AR stimulation (100 nM Iso plus 10 nM ICI 
during 2h) and Ad.PKI-NES (MOI 250) with β1-AR stimulation (100 nM Iso plus 10 nM ICI 
during 2h). Data of ICER mRNA expression in Ad.β-Gal-transduced cells with or without β1-
AR stimulation are the same as in Supplementary Figure 6C. Number of cells/rats (B) or rats 
(C) are indicated in the respective panels. Statistical significance is indicated as *** p<0.001 
between β-Gal and PKI-NES by nested ANOVA with Tukey’s post-hoc test (B) or as ** 
p<0.01 versus β-Gal by Kruskal-Wallis test with Dunn’s post-hoc test (C). 
 
Figure 6: The scaffold protein mAKAPβ controls β2-AR induced nuclear PKA activity 
when PDE4 is inhibited.  
(A) Immunocytochemical detection of mAKAPβ in ARVMs 72h after sequential infection with  
adenoviruses encoding either a scrambled shRNA (Ad.Control shRNA MOI 2000) or a 
shRNA against mAKAPβ (Ad-mAKAPβ shRNA MOI 2000) for 48h followed by infection with 
Ad.AKAR3-NLS (MOI 1000) for 24 h. Scale bars represent 20 µm. (B) Quantification of 
mAKAPβ fluorescence in ARVMs co-transduced with Ad.AKAR3-NLS and Ad.Control shRNA 
or Ad-mAKAPβ shRNA at 72 h. (C) Mean variation of the YFP/CFP ratio upon β1-AR 
stimulation with 3 nM Iso plus 10 nM ICI in ARVMs co-transduced with Ad.AKAR3-NLS and 
Ad.Control shRNA or Ad.AKAR3-NLS and Ad.mAKAPβ shRNA. (D) Mean variation of the 
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YFP/CFP ratio upon β1-AR stimulation with 1 nM Iso plus 10 nM ICI in the presence of 10 µM 
Ro 201724 (Ro) to block PDE4. ARVMs were co-transduced with Ad.AKAR3-NLS and 
Ad.Control shRNA or with Ad.AKAR3-NLS and Ad.mAKAPβ shRNA. (E, F) Mean variation of 
the YFP/CFP ratio upon β2-AR stimulation (using 30 nM Iso plus 100 nM CGP) alone (E) or 
in the presence of 10 µM Ro (F) in ARVMs co-transduced with Ad.AKAR3-NLS and 
Ad.Control shRNA or with Ad.AKAR3-NLS Ad-mAKAPβ shRNA. Number of cells/rats are 
indicated in brackets. Statistical significance is indicated as * p<0.05; ** p<0.01 by nested 
ANOVA with Tukey’s post-hoc test. 
 
Figure 7: Proposed model for β1- and β2-AR regulation of cytoplasmic and nuclear 
PKA activity and ICER expression in adult cardiac myocytes. 
Stimulation of β1-ARs generate cAMP signals (in red) diffusing in the cytoplasm and the 
nucleus. Upon β1-ARs stimulation, PDE4 (in green) regulates cAMP levels to control PKA 
activity in the cytoplasm. A fraction of catalytic subunits (C) of PKA dissociate from regulatory 
subunits (R) and translocate inside the nucleus to increase nuclear PKA activity. Elevation of 
nuclear PKA activity allows induction of ICER transcription, presumably through CREB 
phosphorylation, which may be direct or indirect (dotted arrow between C and CREB). 
Stimulation of β2-ARs also generate cAMP elevation in the cytoplasm and the nucleus 
resulting in activation of cytoplasmic PKA. Cytoplasmic PKA activation upon β2-AR 
stimulation is restricted by caveolin3, Gi, GRK2, PDE3 and PDE4. In addition, PDE4 prevents 
activation by β2-ARs of a specific pool of PKA tethered by mAKAPβ at the perinuclear 
membrane (illustrated by the dotted line surrounding the mAKAPβ-PKA-PDE4 complex) 
which controls access of C subunits to the nucleus (dotted arrow) and nuclear PKA activation 
by β2-ARs. When PDE4 is inhibited, nuclear PKA activation contributes to ICER up-regulation 
by β2-ARs, although other PKA-independent mechanisms may be involved. 
 
 
 
 
T im e  (m in )
Y
F
P
/C
F
P
0 3 6 9 1 2 1 5
0 .8
1 .0
1 .2
1 .4
1 .6
1 .8
2 .0
IC I
Is o  1 0  n M
a
b
c
T im e  (m in )
Y
F
P
/C
F
P
0 3 6 9 1 2 1 5 1 8
0 .8
1 .0
1 .2
1 .4
1 .6
1 .8
2 .0
IC I
Is o  1 0  n M
a
b
c
A B
T im e  (m in )
Y
F
P
/C
F
P
0 3 6 9 1 2 1 5
0 .8
1 .0
1 .2
1 .4
1 .6
1 .8
2 .0
C G P
Is o  1 0 0  n M
a
b
c
T im e  (m in )
Y
F
P
/C
F
P
0 3 6 9 1 2 1 5
0 .8
1 .0
1 .2
1 .4
1 .6
1 .8
2 .0
C G P
Is o  1 0 0  n M
a b c
C D
a b c
0.6
2.0
a b c
0.6
2.0
a b c
0.6
2.0
a b c
0.6
2.0
E F G
Bedioune et al. Figure 1
%
 i
n
c
r
e
a
s
e
 i
n
Y
F
P
/C
F
P
0
2 0
4 0
6 0
8 0
C y to p la sm N u c le u s
(9 /3 )
(1 6 /3 )
(1 8 /5 )
(1 3 /3 )
(1 5 /3 )
(1 6 /3 )
* * *
* * *
$$
# # #
IC I (n M )
Is o  (n M )
10 10 10
1 3 10
0
1 0
2 0
3 0
4 0
5 0
%
 i
n
c
r
e
a
s
e
 i
n
Y
F
P
/C
F
P
C y to p la sm N u c le u s
C G P  (n M )
Is o  (n M )
1 0 0 1 0 0 1 0 0
10 30 1 0 0
(1 2 /3 )
(1 2 /3 )(2 0 /3 )(1 5 /4 )
(1 4 /4 )
(1 2 /5 )
***
# # #
C y to p la s m ic  P K A
(%  in c re a s e  in  Y F P /C F P )
N
u
c
le
a
r
 P
K
A
(
%
 i
n
c
r
e
a
s
e
 i
n
 Y
F
P
/C
F
P
)
0 1 0 2 0 3 0 4 0 5 0
0
5
1 0
1 5
2 0
2 5
 1 -A R
Is o  1 -3 -1 0  n M
 2 -A R
Is o  1 0 -3 0 -1 0 0  n M
E F G
C y to p la s m ic  c A M P
(%  in c re a s e  in  C F P /Y F P )
N
u
c
le
a
r
 
c
A
M
P
(
%
 
in
c
r
e
a
s
e
 
in
 
C
F
P
/
Y
F
P
)
0 2 0 4 0 6 0 8 0 1 0 0
0
3 0
6 0
9 0
1 2 0
1 5 0
 1 -A R
Is o  1 -3 -1 0  n M
 2 -A R
Is o  1 0 -3 0 -1 0 0  n M
A B
T im e  (m in )
C
F
P
/Y
F
P
0 5 1 0 1 5 2 0 2 5
0 .5
1 .0
1 .5
2 .0
2 .5
3 .0
3 .5
IC I
1
Is o  (n M )
3 10
a
b
c
d
e
T im e  (m in )
C
F
P
/Y
F
P
0 5 1 0 1 5 2 0 2 5
0 .5
1 .0
1 .5
2 .0
2 .5
3 .0
3 .5
IC I
1
Is o  (n M )
3 10
a
b
c
d
e
T im e  (m in )
C
F
P
/Y
F
P
0 5 1 0 1 5 2 0 2 5
0 .8
1 .0
1 .2
1 .4
1 .6
1 .8
2 .0
C G P 10
Is o  (n M )
30 1 0 0
a
b
c
d
e
C D
0.0
0.7
a b c d e
0.0
0.7
a b c d e
0.0
0.7
a b c d e
T im e  (m in )
C
F
P
/Y
F
P
0 5 1 0 1 5 2 0 2 5
0 .8
1 .0
1 .2
1 .4
1 .6
C G P 10
Is o  (n M )
30 1 0 0
a
b
c
d
e
0.0
0.7
a b c d e
Bedioune et al Figure 2
0
50
100
150
200
250
%
 i
n
c
re
a
s
e
 i
n
C
F
P
/Y
F
P
Cytoplasm Nucleus
ICI (nM)
Iso (nM)
10 10 10
1 3 10
(14/3)
(14/3)
(14/3)
(10/3)
(10/3)
(10/3)
**
$$ ***
$$$
###
£££
0
2 0
4 0
6 0
8 0
1 0 0
%
 i
n
c
r
e
a
s
e
 i
n
C
F
P
/Y
F
P
C y to p la sm N u c le u s
C G P  (n M )
Is o  (n M )
1 0 0 1 0 0 1 0 0
10 30 1 0 0
(1 4 /3 )
(1 7 /3 )
$ $ $
(1 2 /3 )
(1 2 /3 )
(1 2 /3 )
(1 7 /3 )
***
$$
*
#
T im e  (m in )
%
 i
n
c
re
a
s
e
 i
n
Y
F
P
/C
F
P
0 1 2 3 4 5 6
0
1 0
2 0
3 0
 -G a l (1 5 /4 ) C a v 3 D N  (1 3 /4 )
Time (min)
%
 i
n
c
re
a
s
e
 i
n
Y
F
P
/C
F
P
0 1 2 3 4 5 6
0
10
20
30
-Gal (11/4) Cav3DN (10/4)
*
*
T im e  (m in )
%
 i
n
c
re
a
s
e
 i
n
Y
F
P
/C
F
P
0 1 2 3 4 5 6
0
1 0
2 0
3 0
C o n tro l (1 7 /6 ) P T X  (1 8 /6 )
* *
* *
* * *
T im e  (m in )
%
 i
n
c
re
a
s
e
 i
n
Y
F
P
/C
F
P
0 1 2 3 4 5 6
0
1 0
2 0
3 0
C o n tro l (1 3 /6 ) P T X  (1 4 /6 )
A B
E
C
T im e  (m in )
%
 i
n
c
re
a
s
e
 i
n
Y
F
P
/C
F
P
0 1 2 3 4 5 6
0
1 0
2 0
3 0
C o n tro l (1 7 /5 ) M  C D  (2 3 /5 )
* *
* *
*
Time (min)
%
 i
n
c
re
a
s
e
 i
n
Y
F
P
/C
F
P
0 1 2 3 4 5 6
0
10
20
30
Control (14/5) MCD (14/5)
D
Time (min)
%
 i
n
c
re
a
s
e
 i
n
Y
F
P
/C
F
P
0 1 2 3 4 5 6
0
10
20
30
-Gal (15/3) ARKct (19/3)
*
*
Time (min)
%
 i
n
c
re
a
s
e
 i
n
Y
F
P
/C
F
P
0 1 2 3 4 5 6
0
10
20
30
-Gal (12/3) ARKct (14/3)
G H
F
β2-ARs – Cytoplasm β2-ARs – Nucleus
Bedioune et al., Figure 3
AC
T im e  (m in )
%
 i
n
c
re
a
s
e
 i
n
Y
F
P
/C
F
P
0 1 2 3 4 5 6
0
5
1 0
1 5
2 0
 1 -A R
(1 2 /7 )
 1 -A R + C il
(1 9 /7 )
 1 -A R + R o
(1 9 /7 )
**
***
T im e  (m in )
%
 i
n
c
re
a
s
e
 i
n
Y
F
P
/C
F
P
0 1 2 3 4 5 6
0
1 0
2 0
3 0
4 0
5 0
6 0
 1 -A R
(7 /3 )
 1 -A R + C il
(1 1 /3 )
 1 -A R + R o
(9 /3 )
***
***
***
T im e  (m in )
%
 i
n
c
re
a
s
e
 i
n
Y
F
P
/C
F
P
0 1 2 3 4 5 6
0
1 0
2 0
3 0
4 0
 2 -A R
(1 8 /4 )
 2 -A R + C il
(1 7 /4 )
 2 -A R + R o
(1 9 /4 )
$ $
*
***
T im e  (m in )
%
 i
n
c
re
a
s
e
 i
n
Y
F
P
/C
F
P
0 1 2 3 4 5 6
0
5
1 0
1 5
2 0
 2 -A R
(1 4 /5 )
 2 -A R + C il
(1 4 /5 )
 2 -A R + R o
(1 6 /5 )
* *
* *
* * *
D
BCytoplasm Nucleus
E
n
o
rm
a
li
z
e
d
 I
C
E
R
m
R
N
A
 e
x
p
re
s
s
io
n
C
o
n
tr
o
l
 1
-A
R
 1
-A
R
 +
 R
o
 1
-A
R
 +
 C
il
0
1 0
2 0
3 0
4 0
5 0
***
***
***
$$
(1 2 )
(1 2 )
(1 2 )
(1 2 )
F
n
o
rm
a
li
z
e
d
 I
C
E
R
m
R
N
A
 e
x
p
re
s
s
io
n
C
o
n
tr
o
l
 2
-A
R
 2
-A
R
 +
 R
o
 2
-A
R
 +
 C
il
0
5
1 0
1 5
2 0
2 5
***
$ $ $ $$
(1 2 )
(1 2 )
(1 2 )
(1 0 )
Bedioune et al Figure 4
Bedioune et al Figure 5
A B
C
Distance (µm)
F
lu
o
re
s
c
e
n
c
e
 (
A
U
)
0 10 20 30
0
200
400
600
PKI-NES
NESmCherryPKI (aa 1-25)
Time (min)
%
 i
n
c
re
a
s
e
 i
n
Y
F
P
/C
F
P
0 1 2 3 4 5 6 7
0
10
20
30
40
-Gal (10/3) PKI-NES (11/3)
***
***
***
1-AR
PKI-NES AKAR3-NLS Composite
n
o
rm
a
li
z
e
d
 I
C
E
R
m
R
N
A
 e
x
p
re
s
s
io
n

-G
a
l

-G
a
l 
+
  1
-A
R
P
K
I-
N
E
S
 +
  1
-A
R
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
**
(5 ) (5 )
(5 )
AControl shRNA
AKAR3-NLS
mAKAP shRNA
AKAR3-NLS
AKAR3-NLSmAKAP Composite B
Bedioune et al Figure 6
m
A
K
A
P
 f
lu
o
re
s
c
e
n
c
e
 (
A
U
)
C o ntro l s hR N A m A K A P  s hR N A
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
(1 4 1 /8 )
(1 5 2 /8 )
* * *
C
Time (min)
%
in
c
re
a
s
e
 i
n
Y
F
P
/C
F
P
0 1 2 3 4 5 6 7
0
5
10
15
20
25
30
35
Control shRNA
(28/5)
mAKAP shRNA
(27/5)
**
*
D
E
T im e  (m in )
%
in
c
re
a
s
e
 i
n
Y
F
P
/C
F
P
0 1 2 3 4 5 6 7
0
1 0
2 0
3 0
4 0
5 0
C o n tro l s h R N A
(1 5 /3 )
m A K A P  s h R N A
(1 7 /3 )
**
**
**
F
β1-ARs
T im e  (m in )
%
in
c
re
a
s
e
 i
n
Y
F
P
/C
F
P
0 1 2 3 4 5 6 7
0
1 0
2 0
3 0
4 0
5 0
C o n tro l s h R N A
(1 5 /3 )
m A K A P  s h R N A
(1 5 /3 )
β1-ARs + Ro
β2-ARs β2-ARs + Ro
T im e  (m in )
%
in
c
re
a
s
e
 i
n
Y
F
P
/C
F
P
0 1 2 3 4 5 6 7
0
1 0
2 0
3 0
4 0
5 0
C o n tro l s h R N A
(1 4 /3 )
m A K A P  s h R N A
(1 4 /3 )
Bedioune et al Figure 7
β1 AC
RR
CC
PKA
PDE4
PDE4
β2
Cytoplasm AC
PDE3
CREB ICER expression
P
CRE
Nucleus
C
Gi
Gs
GRK2
Cav3
Gs
RR
CC
PKA
CVR-2017-480R1 
 
SUPPLEMENTARY MATERIAL  
 
PDE4 and mAKAPβ are nodal organizers of β2-ARs nuclear 
PKA signaling in cardiac myocytes 
 
Ibrahim Bedioune1, Florence Lefebvre1, Patrick Lechêne1, Audrey Varin1, Valérie 
Domergue2, Michael S. Kapiloff3, Rodolphe Fischmeister1,2, Grégoire Vandecasteele1 
 
 
1INSERM UMR-S 1180, Univ. Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, 
France. 
2Institut Paris Saclay d’Innovation Thérapeutique, UMS IPSIT, Univ. Paris-Sud, Université 
Paris-Saclay, 92296 Châtenay-Malabry, France. 
3Cardiac Signal Transduction and Cellular Biology Laboratory, Interdisciplinary Stem Cell 
Institute, Departments of Pediatrics and Medicine, Leonard M. Miller School of Medicine, 
University of Miami, Miami, FL 33101, United States. 
 
 
CVR-2017-480R1 
2 
 
DETAILED METHODS 
 
Reagents 
Isoprenaline, CGP-20712A, methyl-β-cyclodextrin, filipin III and acetylcholine were from 
Sigma, Ro-20-1724 and Pertussis toxin were from Calbiochem, cilostamide and ICI 118,551 
were from Tocris Bioscience. CE3F4 (6-Fluoro-5,7-dibromo-2-methyl-1-formyl-1,2,3,4-
tetrahydroquinoline) was kindly provided by Pascal Bouyssou (Institut de Chimie Organique 
et Analytique, Orléans, France). 
 
Adenoviruses 
Adenoviruses (Ad.) encoding the cytoplasmic PKA biosensor AKAR3-NES and the nuclear 
sensor AKAR3-NLS were previously described.1 Ad. PKI encoding the rabbit muscle PKI was 
a kind gift from Dr. Hazel Lum (University of Chicago, Illinois).2 Ad.Cav3 and Ad.Cav3DN 
encoding human wild type and a dominant negative mutant of caveolin 3, respectively3 were 
kindly provided by Dr Sian Harding (Imperial College, London) with permission from Dr. 
Tsutomu Imaizumi (Kurume University, Kurume, Japan). Ad. βARK-ct, encoding for the C-
terminal fragment of GRK2 was a generous gift of Dr. Walter Koch (Temple University, 
Philadelphia, USA). Ad. Epac-SH187, Ad. Epac-SH187-3NLS, Ad. PKI-mCherry-NES, and Ad. 
PKI-mCherry-3NLS were generated for this study as indicated below. The scrambled 
(Ad.Control shRNA) and mAKAPβ-specific shRNA (Ad-mAKAPβ shRNA) adenoviruses 
include hairpin sequences based upon rat mAKAP mRNA sequence (NCBI GI:5070430, 
base pairs 7210-7228) expressed under the control of the U6 promoter, as previously 
described: mAKAP siRNA:  
5’-GACGAACCTTCCTTCCGAATTCAAGAGATTCGGAAGGAAGGTTCGTCTTTTT-3’; 
control siRNA:  
5’-GACGAACCCCTGTTCCGAATTCAAGAGATTCGGAACAGGGGTTCGTCTTTTT-3’.4 
 
Isolation, culture and adenoviral transduction of adult rat ventricular myocytes 
All experiments were carried out according to the European Community guiding principles in 
the care and use of animals (2010/63/UE, 22 september 2010), the local Ethics Committee 
(CREEA Ile-de-France Sud) guidelines and the French decree n° 2013-118, 1st February 
2013 on the protection of animals used for scientific purposes (JORF n°0032, 7 February 
2013 p2199, text n° 24). Authorizations to perform animal experiments according to this 
decree were obtained from the Ministère français de l’Agriculture, de l’Agroalimentaire et de 
la Forêt (agreement N° C 92-019-01). 
Male Wistar rats (250–300 g) were anesthetized by intraperitoneal injection of pentobarbital 
(0.1 mg/g) and hearts were excised rapidly and transferred into a cold Ca2+-free Ringer 
CVR-2017-480R1 
3 
 
solution containing (in mM): NaCl 117, KCl 5.7, NaHCO3 4.4, KH2PO4 1.5, MgCl2 1.7, D-
glucose 11.7, Na-phosphocreatine 10, taurine 20, and HEPES 21. Hearts were then 
mounted on Langendorff apparatus and perfused with an oxygenated Ca2+-free Ringer 
solution for 5 minutes, followed by perfusion during 40 minutes at 37°C with the same 
solution containing 1 mg/mL collagenase A (Roche) plus 320 µM EGTA and CaCl2 to reach a 
free Ca2+ concentration of 20-25 µM. The ventricles were then cut off, chopped with scissors, 
filtered through a sterile 500 μm mesh and the cells were allowed to settle down. The 
supernatant was discarded and cells resuspended two times with Ringer solution at 
increasing [Ca2+] to 300 µM, followed by two other resuspensions in a 5 mg/ml BSA-
containing Ringer solution. Finally, isolated cells were resuspended in minimal essential 
medium (MEM) supplemented with 2.5% fetal bovine serum (FBS), 1% 
penicillin/streptomycin, 20 mM HEPES (pH 7.6), plated on laminin-coated (10 µg/ml) culture 
dishes and kept in a 5% CO2 incubator at 37°C. After 1 to 2 h, the medium was replaced by 
FBS-free MEM with or without adenoviruses. 
 
Western Blot 
ARVMs were lysed in cold lysis buffer containing (in mM): NaCl 150, HEPES 20, EDTA 2, 
Glycerol 10%, Triton 0.2% supplemented with phosphatase inhibitor cocktail (Roche) and a 
protease inhibitor cocktail (Roche). The lysates were centrifuged for 10 minutes at 12,000 g 
and 4°C and proteins from the supernatant were quantified using BCA Protein Assay 
(Pierce). After heating the samples at 95°C for 5 minutes, proteins were subjected to SDS-
PAGE then transferred onto PVDF membranes. The membranes were saturated with 3% 
milk for 1 hour at room temperature and incubated overnight at 4°C with anti-GRK2 antibody 
(sc-562, Santa Cruz), anti-Caveolin-3 (sc-5310, Santa Cruz) and anti-GAPDH (D16H11, Cell 
Signalling). After incubation with appropriate secondary antibodies for 1 hour, proteins were 
visualized by enhanced chemoluminescence. Blots were scanned and analyzed 
densitometrically by ImageJ (National Institute of Health). 
 
Subcellular PKA activity and cAMP measurements by FRET imaging 
Prior to FRET experiments, FBS-free MEM was replaced by a Ringer solution containing (in 
mM): NaCl 121.6, KCl 5.4, MgCl2 1.8, CaCl2 1.8, NaHCO3 4, NaH2PO4 0.8, D-glucose 5, Na-
pyruvate 5, HEPES 10 (pH 7.4). ARVMs were left in this solution during 2 h at room 
temperature for equilibrium before starting acquisition. Images were captured every 5 
seconds using the 40× oil immersion objective of an inverted microscope (Nikon) connected 
to a software-controlled (Metafluor, Molecular Devices) cooled charge coupled (CCD) 
camera (Cool SNAP HQ2). CFP was excited during 300 ms by a Xenon lamp (100W, Nikon) 
using a 440/20BP filter and a 455LP dichroic mirror. Dual emission imaging of CFP and YFP 
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was performed using a Dual-View emission splitter equipped with a 510LP dichroic mirror 
and 480/30 nm, 535/25 nm BP filters. Average fluorescence intensity was measured in a 
region of interest comprising a significant portion of the cytoplasm for Epac-SH187 and 
AKAR3-NES or a region of interest inside one of the two nuclei for Epac-SH187-3NLS and 
AKAR3-NLS. Background was subtracted and CFP bleed through in the YFP channel was 
corrected before calculating the YFP/CFP ratio for the AKAR3 sensors or the CFP/YFP ratio 
for Epac-SH187 sensors. Ratio images were obtained using Image J software.  
 
Pertussis toxin and methyl-β-cyclodextrin treatments 
Culture medium was replaced with fresh FBS-free MEM supplemented or not with Pertussis 
toxin (PTX; 1.5 µg/mL) and ARVMs were then incubated for 2 h in a 5% CO2 incubator at 
37°C. Similar protocol was used for ARVMs treatment with methyl-β-cyclodextrin (MβCD). 
ARVMs were incubated with fresh FBS-free MEM supplemented or not with MβCD (2 mM) 
for 1 h at 37 °C. Thereafter, PTX/MβCD solution was replaced with a Ringer solution and 
ARVMs were used after 2 h.  
 
Gene construction and adenoviral vector generation 
PKI-mCherry-NES and PKI-mCherry-3NLS fusion genes were generated by sequential 
subcloning. The first 25 amino acids of PKI were amplified by PCR (forward primer, 
5’_AATAATAAGCTTATGACTGATGTCGAAACTACTTATGCCG; reverse primer, 
5’_AATAATGGATCCATCGTGGATGGCGTTACGTC) from the full length rabbit muscle PKIα 
(a gift of Dr. Richard A. Maurer, Oregon Health Sciences University) and ligated into the 
HindIII and BamHI sites of the mammalian expression vector, pcDNA3 (Invitrogen). An 
mCherry DNA coding sequence (a gift of Dr. Christian Poüs, University Paris-Sud, France) 
without the stop codon was amplified by PCR (forward primer, 
5’_AATAATGGATCCATGGTGAGCAAGGGC; reverse primer, 
5’_AATAATGAATTCTTCTTGTACAGCTCGTCCATGC) and subcloned at the 3’-end of PKI 
1-25 using BamHI and EcoRI sites of pcDNA3. A DNA oligonucleotide encoding the NES 
sequence (LPPLERLTL) and a stop codon was synthesized (forward, 
5’_AATTCACTGCCCCCCCTGGAGCGCCTGACCCTGTAAT; reverse, 
5’_CTAGATTACAGGGTCAGGCGCTCCAGGGGGGGCAGTG, Eurofins scientific) and 
subcloned at the 3’-end of the PKI-mCherry construct using EcoRI and XbaI sites of pcDNA3 
to obtain the PKI-mCherry-NES fusion gene. The PKI-mCherry sequence was subcloned at 
the 5’-end of a triple NLS sequence (PKKKRKVDPKKKRKVDPKKKRKV) contained into a 
modified pcDNA3 vector using HindIII and EcoRI restriction sites to obtain the PKI-mCherry-
3NLS fusion gene. 
CVR-2017-480R1 
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To obtain the Epac-SH187-3NLS fusion gene, a triple NLS sequence was subcloned at the 3’- 
end of Epac-SH187 using EcoRI and StuI restriction sites. Epac-SH1875 and the triple NLS 
pcDNA3 were gifts of Dr. Kees Jalink (Netherlands Cancer Institute). 
PKI-mCherry-NES, PKI-mCherry-3NLS and Epac-SH187-3NLS were cloned into the pShuttle-
CMV vector (Addgene plasmid # 16403) and transferred by homologous recombination into 
the pAdEasy-1 vector (Addgene plasmid # 16399). The resultant recombinant plasmid was 
digested with PacI and transfected into HEK-293 cells to generate adenoviral vectors. Viral 
particles were harvested and purified with a Vivapure AdenoPACK20 kit (Sartorius). 
 
Real-time quantitative PCR analysis of ICER mRNA induction 
ARVMs were treated with the different drugs and maintained in culture medium for 2 h in a 
5% CO2 incubator at 37 °C. Thereafter, total RNA was extracted using Trizol reagent 
(MRCgene). Reverse transcription of RNA samples was carried out by using iScript cDNA 
synthesis kit (Bio-Rad) according to manufacturer’s instructions.  
Real-time PCR reactions were prepared using SYBR Green Supermix (Bio-Rad) and 
performed in a CFX96 TouchTM Real-Time PCR Detection System (Bio-Rad). 
The relative amount of ICER mRNA transcripts was quantified using the Ct method. The 
average Ct obtained in non-treated cells was used as a calibrator and RPLP2, RPL32, 
YWHAZ housekeeping genes were used as the reference for normalization. The following 
primer pairs were used: 
ICER: 5'_TGGCTGTAACTGGAGATGAAA, 5'_TCTGCTAGTTGCTGGGGACT. 
RPLP2: 5'_GCTGTGGCTGTTTCTGCTTC, 5'_ATGTCGTCATCCGACTCCTC. 
RPL32: 5'_GCTGCTGATGTGCAACAAA, 5'_GGGATTGGTGACTCTGATGG. 
YWHAZ: 5'_AGACGGAAGGTGCTGAGAAA, 5'_GAAGCATTGGGGATCAAGAA. 
 
Immunocytochemistry 
Caveolin-3 and mAKAP detection in cultured cardiomyocytes was analyzed by 
immunocytochemistry using an anti-Caveolin-3 (sc-5310, Santa Cruz, 1:300) and anti-
mAKAP (PRB-451P, BioLegend, 1:1000) respectively. After washing with PBS, ARVMs were 
fixed with 4% PFA in PBS for 15 minutes. Cells were then permeabilized with 0.3% Triton X-
100 in PBS for 30 minutes and incubated for 15 minutes at room temperature with a blocking 
buffer solution containing 0.5% BSA and 1% Goat serum in PBS. Thereafter, the 
preparations were sequentially incubated overnight at 4°C with the anti-Caveolin-3 or 2 h at 
room temperature with the anti-mAKAP primary antibodies and Alexa fluorescent dye-
conjugated specific-secondary antibodies (Alexa Fluor 633, Invitrogen, 1:1000) diluted in 
blocking buffer. Coverslips were mounted on slides using Mowiol coverslip mounting solution 
and imaged using a Leica TCS SP5 confocal microscope equipped with a 60× water 
CVR-2017-480R1 
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immersion objective. For Filipin straining, PFA-fixed cells were incubated with a 50µg/ml 
Filipin-containing PBS solution during 2 h followed by PBS wash. Images were then 
acquired. 
 
Deconvolution 
Confocal images were subjected to spatial deconvolution algorithm. The point spread 
function (PSF) generated by using 0.17 μm orange fluorescent beads (PS-Speck microscope 
point source kit; Molecular Probes) was used in deconvolution. The Richardson-Lucy 
deconvolution algorithm with 10 iterations was performed on each z-stack of images using 
the DeconvolutionLab plugin of ImageJ (Biomedical Imaging Group, EPFL). 
 
Ca2+ imaging 
24 h after transduction with Ad-β-Gal, Ad-PKI-NES or Ad-PKI-3NLS, isolated cardiomyocytes 
were loaded with 1 μM Fura-2 AM (Invitrogen) for 15 min and then washed for 15 min with 
Ringer solution to allow hydrolysis of the esterified groups by endogeneous esterases. 
Loaded myocytes were paced at 1 Hz and Fura-2 ratio (measured at 512 nm upon excitation 
at 340 and 380 nm) was recorded using a double excitation spectrofluorimeter coupled with a 
video detection system (IonOptix, Milton, MA, USA). ARVMs were perfused with normal 
Ringer solution for 3 min (same composition as for FRET imaging), and then the cells were 
stimulated with Isoproterenol. Ca2+ transient amplitude corresponding to the percentage of 
variation between the end-diastolic and the peak systolic Fura-2 ratio was calculated offline 
on dedicated software (IonWizard 6×, IonOptix). 
 
Statistics 
All results are expressed as mean ± SEM. For RT-qPCR data, normal distribution was tested 
by a Shapiro-Wilk normality test. For normally distributed data, differences between multiple 
groups were analyzed using an ordinary one-way ANOVA with Tukey’s multiple comparisons 
post-hoc test. A Kruskal Wallis test with Dunn’s multiple comparisons post-hoc test were 
used when the data did not follow a normal distribution. A nested ANOVA (which takes into 
account both the number of observations and the number of animals) was performed using 
the lme function in the nlme v3.1–131 package for R (R version 3.4.1 and RStudio version 
1.0.153), followed by Tukey’s post-hoc test for all data obtained on individual cells. 
Differences with p values <0.05 were considered as statistically significant. The number of 
independent experiments performed is indicated in the figures. 
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Supplementary Figure 1: Specificity of β1- and β2-AR stimulation by a combination of isoprenaline (Iso) and ICI 118551 (ICI) or Iso and 
CGP 20712A (CGP). (A-C) Representative time course of the normalized YFP/CFP ratio in ARVMs transduced with Ad.AKAR-NES at MOI 
1000 for 24h. (A) Specific β1-AR stimulation using 100 nM Iso in combination with 10 nM ICI was fully blocked by subsequent addition of 100 
nM CGP. (B) Specific β2-AR stimulation with 100 nM Iso in combination with 100 nM CGP was fully blocked by subsequent addition of 10 nM 
ICI. (C) Combined application of 10 nM ICI and 100 nM CGP completely prevented PKA activation by Iso 100 nM. (D-F) Mean variation (±SEM) 
of the YFP/CFP ratio upon (D) β1-AR stimulation before and after addition of 100 nM CGP; (E) β2-AR stimulation before and after addition of 10 
nM ICI; (F) after addition of 100 nM Iso to cells perfused with 10 nM ICI and 100 nM CGP. In D-F, numbers in brackets indicate cells/animals. 
Statistical significance is indicated as *** p<0.001 by nested ANOVA with Tukey’s post-hoc test.   
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Supplementary Figure 2 Epac-SH187-3NLS harbors increased sensitivity to isoprenaline compared to Epac-SH187 (A,B), Representative 
confocal images of ARVMs transduced with Ad.Epac-SH187 or Ad. Epac-SH187-3NLS at MOI 1000 for 24h (A) and 48h (B). In (B), white 
rectangles show the regions of interest where FRET measurements are performed. Scale bars represent 20 µm. (C) CFP/YFP ratio variation in 
the cytoplasmic compartment of ARVMs expressing either Epac-SH187 or Epac-SH187-3NLS after stimulation with the indicated concentrations of 
Isoprenaline. Numbers in brackets indicate cells/animals. Statistical significance is indicated as *** p<0.001 by nested ANOVA with Tukey’s 
post-hoc test. 
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Supplementary Figure 3: Validation of Pertussis toxin as an efficient way to inhibit Gi- mediated signaling and of adenoviral infection 
to overexpress β-ARK-ct in ARVMs. (A) Effect of 1 µM acetylcholine (ACh) on β1-AR response to 10 nM Iso plus 10 nM ICI in ARVMs 
transduced with Ad.AKAR3-NES at MOI 1000, 24h and treated or not with 1.5 µg/mL Pertussis toxin (PTX). (B) Mean variation (±SEM) of the 
YFP/CFP ratio in ARVMs expressing AKAR3-NES upon ACh application on top of β1-AR stimulation using 10 nM Iso plus 10 nM ICI in ARVMs 
treated or not with PTX. Number of cells/animals is indicated in brackets. Statistical significance is indicated as *** p<0.001 by nested ANOVA 
with Tukey’s post-hoc test. (C) βARK-ct expression in ARVMs 48h after co-transduction with Ad.AKAR3-NES (MOI 200) and Ad.β-Gal (MOI 
1000) or Ad.βARK-ct (MOI 1000). GRK2 was used as loading control. 
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Supplementary Figure 4: Validation of methyl-β-cyclodextrin treatment to deplete 
cholesterol, of adenoviral transduction efficiency to overexpress wild type and 
dominant negative caveolin-3 (Cav3) mutant, and effects of Cav3 overexpression on 
PKA responses to β2-ARs stimulation in ARVMs. (A) Effect of MβCD treatment (2 mM, 
1h) on cholesterol content in ARVMs, as assessed by filipin (50 µg/mL) staining. Top, 
representative epifluorescence images of control (non-treated) and MβCD-treated ARVMs 
stained with filipin. Scale bars represent 20 µm. Bottom, average filipin fluorescence intensity 
in control and MβCD-treated ARVMs (number of cells/animals is indicated in brackets). AU, 
arbitrary units. *** p<0.001 by nested ANOVA with Tukey’s post-hoc test. (B) 
Immunocytochemical detection of Cav3 in ARVMs co-transduced with Ad.AKAR3-NES (MOI 
200) and Ad. β-Gal (MOI 2000) or Ad-Cav3 (MOI 2000) or Ad.Cav3DN (MOI 2000) after 48h. 
(C) Western blot analysis of Cav3 and Cav3DN protein expression in ARVMs co-transduced 
with Ad.AKAR3-NES and Ad.β-Gal or Ad.Cav3 or Ad.Cav3DN (same MOI and duration as in 
B). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as loading control. 
Number of animals is indicated in brackets. (D, E) Mean variation (±SEM) of the YFP/CFP 
ratio upon β2-AR stimulation using 30 nM Iso plus 100 nM CGP in ARVMs co-transduced 
with Ad.AKAR3-NES (D) or Ad.AKAR3-NLS (E) (both at MOI 200 for 48h) and Ad.β-
galactosidase (β-Gal, MOI 2000) or Ad.Caveolin-3 (Cav3, MOI 2000). Numbers in brackets 
indicate cells/animals. 
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Supplementary Figure 5: Regulation of ICER mRNA expression by β1-ARs, PDE3 and PDE4 in ARVMs. (A) Effects of PDE4 inhibition with 
10 µM Ro or of PDE3 inhibition with 1 µM Cil during 2h on ICER mRNA expression in ARVMs in primary culture for 24h. (B) ICER mRNA 
expression in ARVMs transduced with Ad.β-Gal (MOI 1000) or Ad.PKI (PKA inhibitor, MOI 1000) for 48 h and stimulated or not with 100 nM Iso 
plus 10 nM ICI during 2h.Number of rats used is indicated in brackets. Statistical significance is indicated as *** p<0.001 versus β-Gal; $ p<0.05 
by Kruskal-Wallis test with Dunn’s post-hoc test. 
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Supplementary Figure 6: Nuclear PKA activation is required for ICER mRNA induction 
by β1-ARs stimulation alone and with concomitant PDE4 inhibition. (A) Top, domain 
scheme of the nuclear-targeted PKA inhibitor, PKI-3NLS. Middle, confocal image of an 
ARVM transduced with Ad.PKI–3NLS (MOI 250, 24h). Scale bar represents 20 µm. Bottom, 
fluorescence intensity profile along the yellow line as indicated on the above image in 
arbitrary units (AU). aa, amino acids. (B) Top, confocal images of ARVMs co-transduced with 
Ad.PKI-3NLS (MOI 250) and Ad.AKAR3-NLS (MOI 1000) for 24h. Scale bars represent 20 
µm. Bottom, Average time course of the YFP/CFP ratio upon β1-AR stimulation using 10 nM 
Iso plus 10 nM ICI in ARVMs co-transduced with Ad.AKAR3-NLS and Ad.PKI-3NLS. ARVMs 
co-transduced with Ad.AKAR3-NLS (MOI 1000) and Ad.β-Gal (MOI 250) were used as 
control. (C) ICER mRNA expression in ARVMs transduced during 24h with Ad.β-Gal alone 
(MOI 250), Ad.β-Gal with β1-AR stimulation (100 nM Iso plus 10 nM ICI during 2h) and 
Ad.PKI-3NLS (MOI 250) with β1-AR stimulation (100 nM Iso plus 10 nM ICI during 2h). Data 
of ICER mRNA expression in Ad.β-Gal-transduced cells with or without β1-AR stimulation are 
the same as in Figure 5C. (D) ICER mRNA expression in ARVMs transduced as in C and 
stimulated or not by β1-AR in the presence of 10 µM Ro. Numbers of cells/rats (B) or rats (C, 
D) are indicated in brackets in each panel. Statistical significance is indicated as *** p<0.001 
by nested ANOVA with Tukey’s post-hoc test in (B) and ** p<0.01; *** p<0.001 versus β-Gal; 
$$$ p<0.001 by Kruskal-Wallis test with Dunn’s post-hoc test in (C, D). 
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Supplementary Figure 7: Nuclear PKA, but not Epac1, contributes to ICER mRNA induction by β2-AR stimulation with concomitant 
PDE4 inhibition. (A) Average time course of the YFP/CFP ratio upon β2-AR stimulation using 30 nM Iso plus 100 nM CGP in the presence of 
10 µM Ro 201724 (Ro) to block PDE4 in ARVMs co-transduced with Ad.AKAR3-NLS (MOI 1000) and Ad.PKI-3NLS (MOI 250). ARVMs co-
transduced with Ad.AKAR3-NLS (MOI 1000) and Ad.β-Gal (MOI 250) were used as control. Number of cells/rats are indicated in brackets. (B) 
Effects of β2-AR stimulation (100 nM Iso plus 100 nM CGP during 2 h) with concomitant PDE4 inhibition (Ro, 10 µM) on ICER mRNA 
expression in ARVMs transduced during 24 h with Ad.β-Gal (MOI 250) or Ad.PKI-3NLS (MOI 250). (C) Effects of β2-AR stimulation (100 nM Iso 
plus 100 nM CGP during 2h) with concomitant PDE4 inhibition (Ro, 10 µM) on ICER mRNA expression in ARVMs transduced during 24h with 
Ad.β-Gal (MOI 250) and pre-treated or not with 10 µM CE3F4 during 15 min at 37°C. In (B) and (C), number of rats are indicated in brackets. 
Statistical significance is indicated as *** p<0.001 by nested ANOVA with Tukey’s post-hoc test in (A) and *** p<0.001 versus β-Gal; $$$ 
p<0.001 by one-way ANOVA with Tukey’s post-hoc test in (B, C). 
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Supplementary Figure 8: PKI-NES but not PKI-3NLS blocks β-AR stimulation of Ca2+ transients in ARVMs. (A-C) Representative traces 
of Ca2+ transients in Fura-2-loaded ARVMs paced at 1 Hz, and transduced for 24h with Ad.β-Gal at MOI 250 (A), Ad.PKI-3NLS at MOI 250 (B) 
or Ad.PKI-NES at MOI 250 (C), under basal condition or 10 nM Iso stimulation. (D) Mean amplitude (±SEM) of Ca2+ transients before and after 
Iso stimulation in β-Gal, PKI-3NLS and PKI-NES expressing ARVMs. Number of cells/rats are indicated in brackets. Statistical significance is 
indicated as *** p<0.001 by nested ANOVA with Tukey’s post-hoc test. 
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Supplementary Figure 9: Knockdown of mAKAPβ does not modify regulation of cytoplasmic PKA activity by β1- or β2-ARs with 
concomitant PDE4 inhibition. ARVMs were transduced with adenoviruses encoding either a scrambled shRNA (Ad.Control shRNA, MOI 
2000) or a shRNA against mAKAPβ (Ad-mAKAPβ shRNA, MOI 2000) for 48h, followed by infection with Ad.AKAR3-NES (MOI 1000) for 24h. 
FRET imaging was performed at 72h. β1-ARs were stimulated with 3 nM Iso + 10 nM ICI, whereas β2-ARs were stimulated with 100 nM Iso + 
100 nM CGP in the presence of the PDE4 inhibitor Ro 201724 (Ro, 10 µM). Numbers in brackets indicate number of cells/rats. 
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